Navigation Links
IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Date:2/15/2011

SEATTLE, Feb. 15, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today the appointment of H. Stewart Parker as its new Chief Executive Officer and new member of the IDRI board of directors.  Parker is a widely recognized figure in the biotechnology industry, having served as President and CEO of Targeted Genetics Corp. and, formerly, Vice President, Corporate Development at Immunex Corp.

"I look forward to working with Stewart, who represents a balance of entrepreneurial spirit and operational expertise," said Steve Reed, IDRI's Founder and Head of Research and Development.

"I couldn't be more thrilled to join IDRI.  The organization possesses a number of technologies that may have an enormous impact on the health of the world," indicated Parker.  "To support their innovation, IDRI possesses developmental capabilities that are rare in non-profits ― yet urgently needed if global health funding is going to result in products that make a difference."  

Currently a Commercialization Consultant with the Washington Biotechnology & Biomedical Association (WBBA), Parker sits on a number of boards including OncoGenex and C3 Jian Inc. Parker was a long-term board member of Biotechnology Industry Organization (BIO).  She earned an MBA from the University of Washington Foster School of Business.  

"The board conducted an exhaustive international search as we sought the best candidate to lead IDRI," says Franklyn Prendergast, M.D., Ph.D. "Stewart's strength and status as a highly respected CEO made her a unique fit with IDRI's team, as well as with our core values and mission."

The appointment follows the announcement of several new grants that ensures IDRI's continuing success in the area of vaccine development, drug discovery, and diagnostics.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
2. Core Informatics Announces Second Office Location in Cambridge Massachusetts
3. RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard
4. Genesis Biopharma Announces Management and Board Changes
5. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
6. Orexigen® Therapeutics Announces Corporate Realignment
7. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. Pancreatic Cancer Action Network Announces New Initiative to Double the Survival Rate for Pancreatic Cancer Patients by 2020
11. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):